<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422890</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-RELAZA-008</org_study_id>
    <secondary_id>2006-001040-31 (EudraCT Nr.)</secondary_id>
    <nct_id>NCT00422890</nct_id>
  </id_info>
  <brief_title>Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <brief_summary>
    <textblock>
      Efficacy and safety of 5-Azacytidin in the treatment of the haematological relapse in&#xD;
      patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with falling&#xD;
      CD34-chimerism after hematopoietic stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of 5-Azacytidin in the treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with falling CD34-chimerism after hematopoietic stem cell transplantation.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of 5-Azacytidin in the treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with falling CD34-chimerism after hematopoietic stem cell transplantation.</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Azacytidin</intervention_name>
    <description>in case of decreasing CD34 chimerism</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Screening phase:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Patients with CD34+ AML or MDS post-allogeneic HSCT&#xD;
&#xD;
          -  Written patient consent after consultation&#xD;
&#xD;
        Treatment phase&#xD;
&#xD;
          -  AML/MDS: donor chimerism &lt; 80% in the CD34+ subpopulation following allogeneic HSCT in&#xD;
             patients with CD34+ AML or MDS, but with no haematological relapse (blasts &lt; 5% in&#xD;
             bone marrow)&#xD;
&#xD;
          -  Leukocytes &gt; 3 Gpt/l and platelets &gt; 75 Gpt/l (transfusion-independent)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known intolerance to 5-azacitidine or mannitol&#xD;
&#xD;
          -  Uncontrollable infectious disease&#xD;
&#xD;
          -  Patients with active hepatitis B or C or HIV infection&#xD;
&#xD;
          -  Severe hepatic function impairment (ASAT and ALAT may not be above three times the&#xD;
             normal value) or hepatic cirrhosis, or malignant hepatic tumour&#xD;
&#xD;
          -  Renal function impairment (creatinine &gt; twice the normal value, creatinine clearance &lt;&#xD;
             50 ml/min)&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Women of childbearing age, except for those who meet the following criteria:&#xD;
&#xD;
          -  postmenopausal (12 months natural amenorrhoea)&#xD;
&#xD;
          -  postoperative (6 weeks after bilateral ovarectomy with or without hysterectomy)&#xD;
&#xD;
          -  regular and correct use of a contraceptive method with an error rate &lt; 1% per year&#xD;
             (e.g. implants, depot injections, combined oral contraceptives, intrauterine device -&#xD;
             IUD, whereby hormonal coils with a Pearl Index of &lt; 1% are safer than copper coils)&#xD;
&#xD;
          -  sexual abstinence&#xD;
&#xD;
          -  Partner vasectomy&#xD;
&#xD;
          -  Men who do not use one of the following for contraception:&#xD;
&#xD;
          -  sexual abstinence&#xD;
&#xD;
          -  post vasectomy&#xD;
&#xD;
          -  condoms&#xD;
&#xD;
          -  Participation of the patient in a drug trial outside the indication of allogeneic&#xD;
             transplantation up to four weeks before study initiation&#xD;
&#xD;
          -  Addictive or other illnesses that prevent the person concerned from comprehending the&#xD;
             nature and impact, as well as potentical consequences of the clinical trial&#xD;
&#xD;
          -  Evidence that the patient may intentionally not comply with the protocol, e.g. lack of&#xD;
             cooperation With the exception of a known allergic reaction or intolerance to&#xD;
             5-azacitidine, these criteria do not apply to the screening phase.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Platzbecker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univesity Hospital Dresden, department of medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University hospital Dresden, department of medicine</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>January 15, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2007</study_first_posted>
  <last_update_submitted>July 8, 2011</last_update_submitted>
  <last_update_submitted_qc>July 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>MD Uwe Platzbecker</name_title>
    <organization>Dresden University of Technology</organization>
  </responsible_party>
  <keyword>Acute myeloid leukaemia or Myelodysplastic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

